期刊
EXPERT REVIEW OF VACCINES
卷 14, 期 9, 页码 1289-1297出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2015.1061938
关键词
DNA vaccine; immune response; protective immunity; ROM4; ROM5; Toxoplasma gondii
类别
资金
- Natural Science Foundation of Gansu Province [1308RJYA092]
- National Natural Science Foundation of China [31172316, 31230073]
- Science Fund for Creative Research Groups of Gansu Province [1210RJIA006]
Objectives: To evaluate the protective efficacy of two novel DNA vaccines expressing Toxoplasma gondii rhomboid 4 (ROM4) and rhomboid 5 (ROM5) proteins against acute and chronic toxoplasmosis. Methods: DNA vaccines (pVAX-TgROM5 and pVAX-TgROM4) were constructed and their immunogenicity evaluated in Kunming mice. Results: Mice vaccinated with pVAX-TgROM5 or pVAX-TgROM4 elicited strong Th1-type humoral and cellular responses, with higher level of IgG antibody titers (the predominance of IgG2a production), and increased levels of CD4(+) and CD8(+) T cells and cytokines IFN-gamma, IL-2, IL-12 (p70) and IL-23. Mice vaccinated with pVAX-TgROM5 (11 days) showed a significantly longer survival time compared with controls (8 days) (p < 0.05) after lethal challenge. Brain cyst numbers of mice vaccinated with pVAX-TgROM5 and pVAX-TgROM4 reduced significantly (p < 0.05) (72.04 and 44.08%, respectively) compared with control groups after chronic challenge. Conclusion: The pVAX-TgROM5 showed a better protective efficacy against acute and chronic toxoplasmosis compared to pVAX-TgROM4.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据